| abstract |
Methods are provided for treating hyperactive diseases and disorders (eg, late-onset dyskinesia). In certain embodiments, the potent VMAT2 inhibitor (+) α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido [2,1- a] Isoquinolin-2-ol ((+) α-HTBZ) is used in the methods described herein to treat a subject in need thereof. In one aspect, in the method of the present invention, (a) tetrabenazine (TBZ); (b) (S) -2-amino-3-methyl-butyric acid (2R, 3R, 11bR) -3-isobutyl-9,10- Dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido [2,1-a] isoquinolin-2-yl ester; (c) deuterated TBZ and the like are administered. |